Cantitate/Preț
Produs
Total produse
Vezi coșul
New Targets in Inflammation de Nicolas Bazan

New Targets in Inflammation

Autor Nicolas Bazan Editat de N. Bazan, Jack H. Botting
en Limba Engleză Hardback
This volume contains the proceedings of the William Harvey Research Conference held in New Orleans on the 15th and 16th of April 1996. It reviews the general pathophysiological significance of the isoforms of cyclooxygenase and the likely value of selective COX-2 inhibitors in the treatment of rheumatoid conditions. The volume also covers the possible use of antibodies against cytokines and cell adhesion receptors in the treatment of inflammatory conditions.
Citește tot Restrânge

Preț: 76270 lei

Preț vechi: 80284 lei
-5% Nou

Puncte Express: 1144
Preț estimativ în valută:
14597€ • 15162$ • 12125£

Carte tipărită la comandă

Livrare economică 01-15 februarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780792387145
ISBN-10: 0792387147
Pagini: 147
Greutate: 0.41 kg

Notă biografică

Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.
Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids.

Cuprins

Preface. 1. The History of Anti-Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2synthase-1 (COX-1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase-2; S.H. Ferreira. 5. Brain COX-2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase-2 Inhibitors; A.W. Ford-Hutchinson. 7. Characteristics of Cyclooxygenase-1 and Cyclooxygenase-2-Deficient Mice; S.G. Morham, R. Langenbach. 8. X-Ray Crystal Structure of Human Cyclooxygenase-2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non-Steroid Anti-Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase-2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX-1/COX-2 Inhibition by Non-Steroid Anti-Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX-2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase-2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.